Trial Profile
Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Subjects
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2022
Price :
$35
*
At a glance
- Drugs Etravirine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Registrational
- Sponsors Janssen R&D Ireland
- 07 Jun 2022 Planned End Date changed from 1 Oct 2031 to 31 Oct 2031.
- 12 Apr 2022 Planned End Date changed from 31 Oct 2031 to 1 Oct 2031.
- 16 Feb 2021 Planned End Date changed from 1 Oct 2031 to 31 Oct 2031.